Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Upcoming clinical trials for these two ASX-listed neuro disease biotechs
News
Trading Places: Which majors bet Megaport can climb out of its slump?
Experts
ScoPo’s Powerplays: Which ASX health stocks are winners from the Federal Budget?
News
ASX Health Stocks: HITIQ lands deal with German ice hockey for its smart mouthguard
Health & Biotech
ASX Health Stocks: Neuren, Imugene and RadioPharm have sights on new clinical trials
Health & Biotech
ASX Health Stocks: Neuroscientific announces breakthrough as Neuren gets ready for Phase 2 trial
Experts
SocPo’s Powerplays: A few healthcare gems among the carnage
Experts
ScoPo’s Powerplays: Healthcare’s game is off, but a comeback is possible
News
December ASX Winners Column: Health and telco stocks plus recapitalised resources companies won the month
News
Winners List: Here are the top 100 ASX small cap stocks for 2021
Health & Biotech
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
News
Hot Money Monday: Investors piled into Neuren last week — are there more gains to come?
News
Weekly Small Cap and IPO Wrap: The ASX’s four-week losing streak…snapped
Health & Biotech
ScoPo’s Powerplays: Neuren breakthrough, M&A deals, and why EBOS ticks ESG boxes
Health & Biotech
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
Health & Biotech
Neuren’s stock price doubles on groundbreaking drug trial, CEO says it’s ‘just getting started’
News